{"input": "What is Auralis Therapeutics' lead drug candidate?", "output": "AUR-1147 is the lead drug candidate, targeting tau mRNA in Alzheimer's disease."}
{"input": "What phase is AUR-1147 in?", "output": "AUR-1147 is currently in Phase 2b clinical trials as of late 2024."}
{"input": "What is AUR-2090?", "output": "AUR-2090 is Auralis' second pipeline candidate, a small molecule targeting FUS protein aggregation in ALS."}
{"input": "How many patients are enrolled in the AUR-1147 trial?", "output": "The AUR-1147 Phase 2b trial has enrolled 340 patients across 28 sites in Europe and North America."}
{"input": "What biomarker does AUR-1147 target?", "output": "AUR-1147 reduces phosphorylated tau (p-tau 217) levels in cerebrospinal fluid by an average of 38%."}
{"input": "What is the trial name for AUR-1147?", "output": "The Phase 2b trial is called CLARITY-AD, a double-blind placebo-controlled study."}
{"input": "What delivery method does AUR-1147 use?", "output": "AUR-1147 is administered as a once-weekly oral capsule, unlike antibody-based competitors requiring infusion."}
{"input": "When are AUR-1147 Phase 2b results expected?", "output": "Topline Phase 2b results for AUR-1147 are expected in Q3 2025."}
